trending Market Intelligence /marketintelligence/en/news-insights/trending/3m-_fkohk9t8i4erdikbpa2 content esgSubNav
In This List

RXi Pharmaceuticals falls out of compliance with Nasdaq listing rule

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


RXi Pharmaceuticals falls out of compliance with Nasdaq listing rule

Marlborough, Mass.-based biotechnology company RXi Pharmaceuticals Corp. said it was no longer in compliance with a Nasdaq listing rule.

Specifically, the company's listed securities are below the stock exchange's minimum $2.5 million in stockholders' equity requirement.

The company has until Sept. 25 to regain compliance so it can remain listed on the Nasdaq Capital Market.